Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffit Hassan

Showing results (111-120 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
The Journal of Pathology. Clinical Research|February 8, 2023
CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesotheliomaShingo Inaguma, Akane Ueki, Jerzy Lasota, et al.
JAMA Dermatology|May 17, 2024
Multiple Onychopapillomas and BAP1 Tumor Predisposition SyndromeAlexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 20, 2021
<i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody AnetumabJyoti Roy, Elaine M Jagoda, Falguni Basuli, et al.
Nuclear Medicine and Biology|July 12, 2011
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibodyIn Soo Shin, Sang-Myung Lee, Hyung Sub Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Plos One|February 25, 2012
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinomaGeng Zhang, Aaron Schetter, Peijun He, et al.
Nature Medicine|July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim resultsRaffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
Cancer Research Communications|December 10, 2025
Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatinPınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2018
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma PatientsSwati Khanna, Suzanne Graef, Francis Mussai, et al.
Pageof 15

Showing results (111-120 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
The Journal of Pathology. Clinical Research|February 8, 2023
CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesotheliomaShingo Inaguma, Akane Ueki, Jerzy Lasota, et al.
JAMA Dermatology|May 17, 2024
Multiple Onychopapillomas and BAP1 Tumor Predisposition SyndromeAlexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, et al.
Cancer Biotherapy & Radiopharmaceuticals|May 20, 2021
<i>In Vitro</i> and <i>In Vivo</i> Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody AnetumabJyoti Roy, Elaine M Jagoda, Falguni Basuli, et al.
Nuclear Medicine and Biology|July 12, 2011
Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibodyIn Soo Shin, Sang-Myung Lee, Hyung Sub Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Plos One|February 25, 2012
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinomaGeng Zhang, Aaron Schetter, Peijun He, et al.
Nature Medicine|July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim resultsRaffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
Cancer Research Communications|December 10, 2025
Targeting uPARAP with an antibody-drug conjugate exhibits efficacy against mesothelioma and synergizes with cisplatinPınar Çakılkaya, Ida Marie Egeland Larsen, Qun Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2018
Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma PatientsSwati Khanna, Suzanne Graef, Francis Mussai, et al.
Pageof 15